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In a recent issue of Cell, Iliopoulos and colleagues demonstrate a novel and targetable epigenetic amplifica-
tion loop in hepatocellular carcinoma involving HNF4a, miR-124, IL6-R, Stat3, miR-24, and miR-629. These
results establish microRNAs as novel players in early stages of hepatocarcinogenesis and as potential
targets for the treatment of hepatocellular carcinoma.Liver cancer is the third leading cause
of cancer mortality worldwide, with an
annual death toll of approximately
700,000. In contrast to the decreasing
mortality rates observed for many other
types of cancers, liver cancer incidence
and overall mortality have significantly
increased in the United States over the
past 20 years (El-Serag, 2011). Risk
factors for hepatocellular carcinoma
(HCC), the most common type of primary
liver cancer, include chronic viral hepatitis,
alcohol abuse, and nonalcoholic fatty liver
disease (El-Serag, 2011). Most HCC
patients are diagnosed at intermediate or
advanced stages, rendering only 15% of
HCC patients eligible for curative thera-
pies such as resection or liver transplanta-
tion. The introduction of the multikinase
inhibitor sorafenib as the first drug with
therapeutic efficacy against HCC repre-
sents the biggest therapeutic advance in
the past decade (Llovet et al., 2008).Major
hurdles in developing effective therapies
against HCC have been its considerable
heterogeneity and the absence of well-
established and broadly targetable onco-
gene addiction. Although inflammation is
a characteristic feature of the environment
in which most HCCs arise, and inflamma-
tory factors including interleukin-6 (IL-6)
promote HCC in mice (Naugler et al.,
2007) and negatively influence outcome
in patients (Hoshida et al., 2008), few ther-
apeutic efforts have been directed at
these pathways.
In a recent paper published in Cell, Ilio-
poulos and colleagues demonstrate a
novel and targetable proinflammatory
pathway through which hepatocytes
may acquire a transformed phenotype
(Hatziapostolou et al., 2011). One of
the outstanding features of this study is
the discovery of an entirely epigenetic
circuit that initiates transformation in the698 Cancer Cell 20, December 13, 2011 ª20absence of genetic alterations. Another
remarkable finding of the study is that
the described epigenetic positive feed-
back circuit can maintain an inflammatory
state through multiple generations of cells
following removal of the initial trigger. This
finding is similar to a previous study in
which Iliopoulos et al. (2009) uncovered
an epigenetic circuit in breast cancer
that maintains inflammation through an
Src-initiated nuclear factor kB (NF-kB)–
Lin28–Let-7–IL-6–NF-kB positive feed-
back loop.
In the present study, the authors focus
on hepatocyte nuclear factor 4a (HNF4a),
a transcription factor that is essential for
the development and differentiation of
hepatocytes (Parviz et al., 2003). Knock-
down of HNF4a in immortalized human
hepatocytes led to cellular transformation
and increased tumor formation after
transplantation into immunosuppressed
mice. Because HNF4a expression was
still suppressed after 2 months, the
authors speculated that a continuous
feedback loop must maintain HNF4a at
low levels in these cells. Step by step,
the authors meticulously uncovered
several components of this feedback
loop (Figure 1). First, the authors identified
microRNAs miR-24 and miR-629 as
potent regulators of HNF4a expression
and confirmed the feedback loop by
demonstrating increased miR-24 and
miR-629 afterHNF4a knockdown. In other
words, knocking down HNF4a activates
mechanisms that subsequently amplify
or perpetuate the knockdown HNF4a.
Overexpression of miR-24 and miR-629
virtually phenocopied the effects of
HNF4a on gene expression, transforma-
tion, and tumor formation. Common to
both miR-24 and miR-629 was the pres-
ence of a signal transducer and activator
of transcription 3 (Stat3) binding site in11 Elsevier Inc.their promoter and their direct regulation
by Stat3 as demonstrated by chromatin
immunoprecipitation assays and Stat3-
dependent induction of their expression
by IL-6. Finally, the missing link between
HNF4a and Stat3 was identified as miR-
124, a microRNA that contains an HNF4a
binding site in its promoter and directly
targets IL-6 receptor (IL-6R), thus closing
the loop to IL-6-mediatedStat3 activation.
The overexpression of Stat3 targets
miR-24 and miR-629 or inhibition of
HNF4a, the inducer of IL-6R repressing
miR-124, all resulted in increased Stat3
phosphorylation, again confirming the
presence of a positive feedback loop.
To test the relevance of this novel
inflammatory circuit in vivo, the authors
delivered miR-124 to the liver during di-
ethylnitrosamine (DEN)-induced hepato-
carcinogenesis. Not only did miR-124
delivery decrease the number and size
of DEN-induced tumors by 90% when
given throughout the entire study, it also
led to a striking 80%decreasewhen treat-
ment was started only 4 weeks before
sacrifice. The authors also confirmed rele-
vance to human hepatocarcinogenesis by
demonstrating downregulation of HNF4a
and its target miR-124, and upregulation
ofmiR-24 and IL-6R in humanHCC.More-
over, there were strong inverse correla-
tions between miR-24 and miR-629 and
their target HNF4a as well as between
miR-124 and its target IL-6R, and a strong
positive correlation between HNF4a and
its target miR-124, thus suggesting the
existence of the same epigenetic regula-
tory circuit in human HCC.
The data by Hatziapostolou et al. add
significantly to the expanding data on mi-
croRNA control in cancer. In the liver,
previous studies have shown that both
up- and downregulation of microRNAs
contribute to liver cancer growth and
Figure 1. Transformation of Hepatocytes by a HNF4a–miR-124–IL6-
R–Stat3–miR-24/miR-629 Amplification Loop
Temporary suppression of HNF4a induces permanent suppression of HNF4a
by a feed-forward amplification loop that includes decreasedmiR-124 expres-
sion after HNF4a suppression, a subsequent increase in IL-6R expression and
Stat3 signaling, and an upregulation of Stat3-inducible and HNF4a-targeting
microRNAs miR-24 and miR-629.
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survival (Ding et al., 2010;
Hou et al., 2011; Ji et al.,
2009). The two surprising
findings of the current study
are the key contribution of
microRNAs to early stages
of carcinogenesis and the
astounding efficacy of micro-
RNA therapy. The finding
that transient suppression of
a single transcription factor,
HNF4a, or overexpression of
miR-24 and miR-629 results
in cellular transformation is
unexpected and represents
a major advance in the field.
However, while the authors
show clear relevance of
HNF4a, miR-24, and miR-
629 in established murine
and human HCC, most of
the data on transformation
by transient HNF4a knock-
down or miR-24 and miR-
629 overexpression are
based on studies in cell lines.
Further in vivo models are
needed to determine whethertemporary knockdown of HNF4a or
combined overexpression of miR-24 and
miR-629 in the liver are indeed sufficient
to trigger carcinogenesis. It is conceivable
that factors generated in the tumor micro-
environment, such as Kupffer cell-derived
IL-6, might also serve to initiate the feed-
forward loop in patients with chronic liver
disease. The finding that miR-124 inhibits
DEN hepatocarcinogenesis raises the
prospect that microRNA-based therapies
may represent a novel avenue to cancer
treatment. While acknowledging that
therapeutic success in mouse models is
not always reproducible in clinical trials
in patients, the demonstrated efficacy of
miR-124 delivery appears unusually
promising. Notably, the profound effects
of miR-124 in advanced stages suggest
that miR-124 may actually regress estab-
lished tumors. These results should be
further confirmed, preferentially in HCCmodels that incorporate the typical
inflammatory and fibrotic microenviron-
ment seen in patients with HCC. Because
tumor cell populations are not homoge-
neous, it would also be important to inves-
tigate whether miR-124-based therapy
affects all tumor cells equally, or whether
subsets of cells, such as cancer stem
cells, might escape from this treatment.
Moreover, the key involvement of IL-6R
in this circuit suggests that IL-6 antago-
nists may be able to interrupt this circuit
and tumor growth.
In conjunction with their previous study
(Iliopoulos et al., 2009), these new data by
Iliopoulos and colleagues indicate that
epigenetic circuits can establish perma-
nent alterations of cellular phenotypes
and drive cancer initiation with a similar
(or greater) potency as genetic alterations
of oncogenes or tumor suppressors. This
will without a doubt reopen the debate asCancer Cell 20, December 13,to whether genetic or epige-
netic alterations represent
the first hit in most human
cancers. The recognition of
a potential tumor-initiating
role for microRNAs may
render tumor cell biology
even more complex—but
also more exciting, as it will
undoubtedly open the door
for new therapies, especially
for difficult-to-treat cancers
such as HCC.REFERENCES
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